The Treatment of Uterine Leiomyosarcoma: Results From a 10-Year Experience (1990–1999) at the Massachusetts General Hospital

Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma?

“…However, approximately 40% will have extra-uterine disease spread at the time of surgery [1]. Recurrence rates range from 53 to 71% for all stages and are often extra-pelvic, multisite and lethal [2][3][4][5][6][7]. Recurrence and prognosis are ultimately dependent upon the mitotic activity, or grade, of the tumor and the stage at presentation.…”

“…The high rate of distant failure, even in the setting of early-stage disease, provides the rationale for consideration of adjuvant systemic therapy [2]. However, the role of adjuvant therapy in completely resected, uterine-limited leiomyosarcoma is unclear.…”

Case report: MR imaging features of disseminated uterine leiomyosarcoma presenting after hysterectomy with morcellation

“…The overall 5-year survival rate for individuals with unsuspected leiomyosarcoma who underwent morcellation is 46% [24]. Prognosis is also poor for uterine leiomyosarcomas even without morcellation with a similar overall 5-year survival of 44-45% [25,26].…”

Strahlentherapie des Uterussarkoms

“…Sie sollte die Hysterektomie mit beiden Adnexen und ein systematisches chirurgisches Staging (pelvine und paraaortale Lymphonodektomie, peritoneale Lavage und ggf. Peritonealbiopsien) beinhalten [2,11,12,13]. Für das chirurgische Vorgehen jedoch weist die vorliegende eine sehr große Heterogenität auf.…”